20 October 2020 | News
To develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
Image credit- shutterstock.com
Samsung Biologics has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
Under this agreement, South Korea based Samsung Biologics will provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing as well as IND filing support.
"Partnering with BioEleven reinforces the key value of our CDO business model: to support our clients with faster and better services in their efforts to help patients in need all around the world," said Dr. Tae Han Kim, CEO of Samsung Biologics. "We thank BioEleven for putting trust in our services, and look forward to seeing what this partnership will accomplish."
BioEleven, a specialized probiotic company, has secured its own probiotics strains over the past decade and is running the first stool bank for FMT (Fecal Microbiota Transplantation) in Korea.